AbbVie’s Recent ImmunoGen Acquisition Looks Brilliant: Here’s Why
Drug patents don't last forever, so pharmaceutical companies are constantly looking for the next big treatment to broaden their total portfolio of offerings.
When it...
Should Investors Buy the Dip in UiPath Stock for 2024?
Fool.com contributor Parkev Tatevosian evaluates UiPath (PATH 1.22%) stock and lets growth stock investors know if they should add it to their portfolios for...
1 Grim Tiding and 2 Silver Linings for Canopy Growth Stock in 2024
Recognizing the positives that are present in a generally negative situation is a key skill in investing and in life. It's also a skill...
Should You Invest in Bluebird Bio Right Now?
Benjamin Graham and Warren Buffett may urge investors to buy when there's blood on the streets, but even the best advice has its limitations....
Palantir Is Up 170% This Year. Can the Rally Continue in 2024?
Palantir (PLTR 1.55%) has taken off this year. After flirting with record lows at the end of last year, the stock climbed steadily higher...
